A detailed history of Allworth Financial LP transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Allworth Financial LP holds 568 shares of TVTX stock, worth $11,274. This represents 0.0% of its overall portfolio holdings.

Number of Shares
568
Previous 568 -0.0%
Holding current value
$11,274
Previous $4,000 75.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 23, 2024

BUY
$5.26 - $8.28 $2,987 - $4,703
568 New
568 $4,000
Q3 2023

Oct 31, 2023

BUY
$7.64 - $17.25 $221 - $500
29 Added 152.63%
48 $0
Q2 2023

Jul 18, 2023

SELL
$15.3 - $22.61 $351 - $520
-23 Reduced 54.76%
19 $0
Q1 2023

Apr 18, 2023

BUY
$17.82 - $22.89 $748 - $961
42 New
42 $0
Q3 2022

Oct 18, 2022

BUY
$22.91 - $28.63 $756 - $944
33 Added 194.12%
50 $1,000
Q2 2022

Jul 13, 2022

BUY
$20.94 - $30.01 $355 - $510
17 New
17 $0

Others Institutions Holding TVTX

About Travere Therapeutics, Inc.


  • Ticker TVTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 64,173,600
  • Market Cap $1.27B
  • Description
  • Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...
More about TVTX
Track This Portfolio

Track Allworth Financial LP Portfolio

Follow Allworth Financial LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Allworth Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Allworth Financial LP with notifications on news.